Elanco Animal Health Incorporated
At today's price, Elanco Animal Health Incorporated (ELAN) is priced for today's economics sustained for ~18.4 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
- At $24.21 the price works out to roughly 135 times company-wide operating income, a multiple that only makes sense if Elanco compounds operating profit at close to its self-funding ceiling for something like eighteen years. The animal-health franchise is durable, but that is a long runway to ask of a business whose trailing operating margin sits near 2.5 percent. - The first quarter of 2026 was the clearest evidence yet that the innovation portfolio is doing real work: revenue of $1.371 billio
Is ELAN overvalued? See what's priced in →
498 institutional managers reported holding ELAN in 13F filings for the quarter ended 2026-03-31. 87 opened new positions that quarter. Held by Dodge & Cox, FMR (Fidelity), Vanguard Group, among others. On the short side, 35.6M shares were sold short as of the 2026-06-15 count, about 7% of shares outstanding (6.4 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
ELAN's share count grew 2.1% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at ELAN over the trailing three years: 2024: 6 buys totaling $2.23M; 2025: 7 buys totaling $1.42M. 26 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
ELAN's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-05-10 | -3.9% | +14.7% |
| 2023-08-08 | +7.0% | -19.5% |
| 2023-11-08 | +15.9% | +40.2% |
| 2024-02-27 | +0.6% | -20.1% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
ELAN's latest 8-K filings: 2026-05-27 (items 5.07); 2026-05-06 (items 2.02, 9.01); 2026-02-24 (items 2.02, 9.01); 2026-01-12 (items 7.01, 9.01); 2025-12-09 (items 2.05, 7.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.